In a move designed to enhance its capabilities within the life sciences sector, Crowell & Moring has completed a merger with Boston-based firm Faber Daeufer & Itrato. This strategic acquisition aims to bolster Crowell’s life sciences and emerging companies portfolio, underscoring the firm’s ambition to expand its influence in this growing industry.
The merger sees Crowell integrate a boutique operation comprising 24 lawyers, which counts Alphabet Inc.’s venture capital arm among its clients. According to Philip T. Inglima, chair of Crowell’s management board, this collaboration is the fruit of a six-month process, reflecting the firm’s intent to enhance its foothold in life sciences and geographic presence in Boston. The city is increasingly being recognized as a crucial hub for technology and healthcare markets, aligning well with Crowell’s strategic goals of deepening its expertise in these areas.
This union signifies not only an increase in Crowell’s legal muscle but also an opportunity to expand its real estate presence in Boston, capitalizing on the city’s demanding tech and healthcare sectors. With this merger, Crowell demonstrates its commitment to advancing its presence and capabilities in a competitive landscape, recognizing the significance of Boston as a prime location to tap into hotbed markets.
Crowell’s ambition to grow its array of life sciences clients is apparent, and this merger with Faber Daeufer & Itrato is a clear statement of intent. As legal practices continue vying for strategic advantage, Crowell’s move highlights its proactive approach in aligning with sectors showing robust growth and demand potential.